

# Unaudited Financial Results (Provisional) For the 2<sup>nd</sup> Quarter and Half Year Ended 30<sup>th</sup> September 2011

(Rs. In Lakhs)

				(KS. IN Lak	
Particulars	3 Months ended 30/09/2011	3 Months ended 30/09/2010	Half Year ended 30/09/2011	Half Year ended 30/09/2010	Financial Year ended 31/03/2011
	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Net Sale/ Income from Operations	1139.70	2628.30	2280.98	3688.35	5599.51
Other Operating Income	0.00	0.00	0.00	0.00	0.00
Expenditure					
\Increase/ Decrease in Stock in trade and					
WIP	4.47	325.31	9.51	306.24	302.45
Purchase / Cost of Operations	1088.55	2253.17	2179.77	3265.73	5094.09
Employee Cost	6.31	9.23	13.42	14.92	30.04
Depreciation	9.30	10.27	18.60	20.53	41.06
Other Expenditure	15.86	17.24	26.98	27.97	53.09
Total	1124.49	2615.22	2248.28	3635.39	5520.73
Profit from operations before other					
income, interest and exceptional items	15.21	13.08	32.70	52.96	78.78
Other Income	3.02	1.56	5.95	4.42	12.62
Profit before interest and exceptional					
items	18.23	14.64	38.65	57.38	91.40
Interest	0.00	0.00	0.00	0.00	0.00
Profit after interest but before					
exceptional items	18.23	14.64	38.65	57.38	91.40
Exceptional items	0.00	0.00	0.00	0.00	0.00
Profit (+)/ Loss (-) from ordinary					
activities before tax	18.23	14.64	38.65	57.38	91.40
Tax Expense	0.00	0.00	0.00	0.00	(80.0)
Net Profit (+)/ Loss (-) from Ordinary					
Activities after tax	18.23	14.64	38.65	57.38	91.48
Extraordinary Item (net of tax expenses)	0.00	0.00	0.00	0.00	0.00
Net Profit (+)/ Loss (-) for the period	18.23	14.64	38.65	57.38	91.48
Paid-up Equity Share Capital (Face Value					
of the Share shall be indicated)	1099.20	1099.20	1099.20	1099.20	1099.20
Face Value of Equity Shares (Re)	1.00	1.00	1.00	1.00	1.00
Reserve excluding Revaluation Reserves					
as per Balance Sheet of previous year					664.42
Earning Per Share (EPS)					
(a) Basic & Diluted EPS before					
Extraordinary items for the period, for					
the year to date and for the previous					
year (not to be annualised)	0.02	0.01	0.04	0.05	0.08

Email: info@mavensbiotech.com

Website: www.mavensbiotech.com

**Corporate Office:** 



		_			
(b) Basic & Diluted EPS after					
Extraordinary items for the period, for					
the year to date and for the previous	1				
year (not to be annualised)	0.02	0.01	0.04	0.05	0.08
Public Shareholding					
- No. of shares	74700010	74700010	74700010	74700010	74700010
- Percentage of shareholding	67.96%	67.96%	67.96%	67.96%	67.96%
Promoters and promoter group			1		
Shareholding					
a) Pledged/ Encumbered					
- Number of shares	0	0	0	0	0
- Percentage of shares (as a % of the					
total shareholding of promoter and					0%
promoter group)	0%	0%	0%	0%	
- Percentage of shares (as a% of the	•			ŀ	
total share capital of the company)	0%	0%	0%	0%	0%
b) Non-encumbered					
- Number of Shares	35219990	35219990	35219990	35219990	35219990
- Percentage of shares (as a% of the					
total shareholding of promoter and					100%
promoter group)	100%	100%	100%	100%	
- Percentage of shares (as a % of the				Ţ	
total share capital of the company)	32.04%	32.04%	32.04%	32.04%	32.04%

## Quarterly Reporting Segment wise Revenue, Results and Capital Employed under Clause 41 of the Listing Agreement

(Rs. In Lakhs)

	3 Months	3 Months	Half Year	Half Year	Financial
	ended	ended	ended	ended	Year ended
Particulars	30/09/2011	30/09/2010	30/09/2011	30/09/2010	31/03/2011
	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Segment Revenue					
(Net Sale/ income from each segment)					
Sale of Commodities & Agro Products	1137.77	2627.28	2279.05	3685.47	5595.55
IT Business	1.93	1.02	1.93	2.88	3.96
Unallocated	0	0	0	0	0
Total	1139.70	2628.30	2280.98	3688.35	5599.51
Less : Inter Segment Revenue	0	0	0	0	0
Net Sales/ Income from operations	1139.70	2628.30	2280.98	3688.35	5599.51
Segment Results	7.00				
(Profit / Loss before tax and interest from each segment)					
Sale of Commodities & Agro Products	18.20	16.66	38.62	62.28	100.67
IT Business	0.15	0.03/	00 150	0.11	0.14

Email: info@mavensbiotech.com - Website: www.mavensbiotech.com



Less : Interest	0	0	0	0	0
Less : Inter Segment Income	0	0	0	0	0
Less: Unallocable Expenditure	0.12	2.05	0.12	5.01	9.41
PBT	18.23	14.64	38.65	57.38	91.40

## **Segment Capital Employed**

Fixed Assets used in the company's business or liabilities have not been identified to any of the reportable segments, as the fixed assets and services are used interchangeably between segments. The management believes that it is currently not practicable to furnish segmental disclosures relating to total assets and liabilities.

### **Disclosure of Assets and Liabilities**

(Amount in Rs.)

Particulars	6 months ended (30/09/2011)	6 Month ended (30/09/2010)
	Unaudited	Unaudited
SHAREHOLDERS' FUNDS:		
(a) Capital	109920000	109920000
(b) Reserves and Surplus	70307439	63031543
LOAN FUNDS	0	0
TOTAL	180227439	172951543
FIXED ASSETS	54276257	54924189
CAPITAL WIP	13177265	13177265
INVESTMENTS	2475160	2475160
CURRENT ASSETS, LOANS AND ADVANCES		
(a) Inventories	30647939	31220690
(b) Sundry Debtors	39681696	40977049
(c) Cash and Bank balances	2088019	2415720
(d) Other current assets	0	0
(e) Loans and Advances	42077200	43393075
Less: Current Liabilities and Provisions		
(a) Liabilities	3820416	2768759
(b) Provisions	375683	12862846
MISCELLANEOUS EXPENDITURE (NOT WRITTEN OFF OR ADJUSTED)	0	0
PROFIT AND LOSS ACCOUNT	0	0
TOTAL	180227439	172951543

#### Notes:

**Corporate Office:** 

The above Unaudited financial results were reviewed by the audit committee and taken on record by Board of Directors at their meeting held on 27/10/2011.

Email: info@mavensbiotech.com

Website: www.mavensbiotech.com

Registered Office:


A-56/A Lajpat Nagar - II, 1st Floor, New Delhi - 110 024 Tel: +91-11-41720778 Fax: +91-11-29847741



- 2. Segment Revenue: Revenue for this quarter/ half year comes from two activities, i.e., Sale of Commodities & Agro Products and IT Business.
- 3. The above results have been subjected to 'Limited Review' by the Statutory Auditor of the company
- 4. Provision for taxations will be made at the end of the year.
- 5. There were no complaints pending at the beginning of the quarter and no complaints were received from the investors during the quarter.
- 6. Figures of the previous period have been regrouped wherever necessary.

By Order of the Board For Mavens Biotech Limited

Date: 27/10/2011 Place: Kolkata



Sd/-Director

Email: info@mavensbiotech.com